Table 2. Comparison of sputum autoantibody levels among groups (MFI).
| Characteristic | Controls | Eosinophilic COPD | Non–eosinophilic COPD | P |
|---|---|---|---|---|
| Anti-La_IgG | 3,902.95 (3,591.98–4,598.25) | 3,932.6 (3,321.4–4,834.25) | 3,838.8 (3,177.6–4,648.63) | 0.738 |
| Anti-Aβ_IgG | 87 (61.38–105.35) | 76.05 (49.85–94.13) | 71.45 (28.08–113.8) | 0.690 |
| Anti-HSP70_IgG | 5,647.1 (4,971.73–7,300.7) | 4,797.2 (4,155.95–5,519.38) | 4,793.9 (4,283.2–6,739.95) | 0.062 |
| Anti-Elastin_IgG | 703.65 (541.53–787.15) | 603.2 (459.98–740.58) | 576.75 (421.1–850.98) | 0.300 |
| Anti-CENPB_IgG | 2,980.4 (2,710.78–4,263.58) | 2,994.55 (2,444.63–3,537.35) | 2,661.45 (2,441.18–3,364.6) | 0.200 |
| Anti-Cytokeratin18_IgG | 1,500.15 (546.38–2,919.4) | 748.3 (425.05–1,783.38) | 724.55 (337.8–2565.48) | 0.484 |
| Anti-CollagenI_IgG | 229.4 (184.9–403.18) | 246.35 (211.03–339.25) | 200.25 (168.85–336.88) | 0.560 |
| Anti-CytochromeC_IgG | 703.25 (583.68–850.53) | 805.95 (648.53–1,014.05) | 908.05 (755.1–1,072.18)a | 0.048 |
| Anti-CollagenII_IgG | 491.2 (275.4–873.65) | 262.55 (188.43–321.33)a | 228.6 (166.23–337.65)a | 0.015 |
| Anti-HSP47_IgG | 352.9 (223.25–751.2) | 184.65 (108.13–287.03)a | 235.45 (133.9–580.85) | 0.013 |
| Anti-CollagenIV_IgG | 170 (90.65–455.25) | 97.15 (46.63–329.13) | 45 (33.65–154.63)a | 0.046 |
| Anti-Vimentin_IgG | 293.1 (247.15–599.28) | 267.15 (220.45–394.4) | 292.15 (163.58–394.78) | 0.518 |
| Anti-Aggrecan_IgG | 524.2 (456.25–734.1) | 566 (501.93–623.8) | 618.9 (509.63–661.18) | 0.816 |
| Anti-La_IgM | 5,384.9 (4,491.95–7,136.75) | 4,748.6 (4,058.8–6,233.4) | 5,390.8 (4,359.58–9,008.48) | 0.347 |
| Anti-Aβ_IgM | 56.6 (0–109.53) | 17.65 (0.53–54.68) | 26.85 (1.13–61.73) | 0.501 |
| Anti-HSP70_IgM | 5,666 (4,270.83–7,225.2) | 5,131.15 (4,291.88–8,496.28) | 5,993.25 (4,165.58–9,503.95) | 0.852 |
| Anti-Elastin_IgM | 10,041.5 (8,136.6–11,624.85) | 9,209.95 (5172.88–10,604.28) | 9,639.15 (7,659.4–11,446.43) | 0.252 |
| Anti-CENPB_IgM | 4,046.35 (2,308.8–6,839.7) | 3,725.75 (2,535.5–7,637.63) | 2,915.3 (2,436.78–6,770.15) | 0.880 |
| Anti-Cytokeratin18_IgM | 3,375.15 (1,333.8–4,391.28) | 2,291.75 (1,092.98–7,606.2) | 1,670.4 (1,090.83–6,296.05) | 0.969 |
| Anti-CollagenI_IgM | 214.65 (0–348.05) | 183.75 (78.28–424.2) | 147.4 (14.65–388.28) | 0.540 |
| Anti-CytochromeC_IgM | 8,662.8 (8,164.45–13,865.6) | 8,561.15 (7,942.75–9,575.38) | 8,667.05 (7,946.78–11,466.05) | 0.770 |
| Anti-CollagenII_IgM | 259.5 (0–2,062.28) | 503.1 (18.75–1781.8) | 295 (1.2–658.73) | 0.321 |
| Anti-HSP47_IgM | 240.65 (133.33–503.48) | 280.8 (127.68–574.98) | 287.65 (80.45–917.45) | 0.758 |
| Anti-CollagenIV_IgM | 0.4 (0–51.35) | 10.1 (0–210.83) | 1.2 (0.25–37.65) | 0.365 |
| Anti-Vimentin_IgM | 656.75 (342.2–1,374.78) | 351.4 (262.35–715.95) | 445.05 (265.45–980.93) | 0.498 |
| Anti-Aggrecan_IgM | 0 (0–314.73) | 241.5 (1.18–587.98)a | 413.1 (1.2–721.2)a | 0.018 |
Eosinophilic COPD is defined as ≥3% sputum eosinophils, and non-eosinophilic COPD is defined as <3% sputum eosinophils. Aβ: amyloid-beta; MFI: mean fluorescence intensity; HSP47: heat shock protein 47; HSP70: heat shock protein 70; La: La/Sjögren syndrome type B antigen; CENP-B; centromere protein B. aP<0.05 vs. control group.